Introduction
============

Sarcopenia is an age-related disease characterized by the loss of muscle mass and muscle function, and it leads to an increased risk of adverse outcomes such as falling, functional limitation, disability, and mortality in elderly people ([@ref-15]; [@ref-25]).

The age-associated reduction in muscle mass, the main parameter of sarcopenia, is complex as it involves multi-biological processes. Although there are multiple types of molecular pathology, including mitochondrial dysfunction, insulin resistance, inflammatory states and loss of *α*-motor, and biological changes, that participate in the development of the aging of muscle mass ([@ref-38]; [@ref-48]), the primary cause of sarcopenia is unclear. Also, these changes in muscle mass are regulated through different mechanisms in men and women ([@ref-27]).

A better understanding of molecular pathology would provide a greater insight into the aging process of muscle mass and could be beneficial to early diagnosis and prevention of aging-related diseases such as sarcopenia. Recently, the use of microarrays as a powerful technique has been utilized to identify a global view of the molecular changes in various states. In previous studies, this tool has been used to research the impact of aging on muscle mass ([@ref-33]; [@ref-53]). Also, to identify the molecular mechanisms of sarcopenia, several studies have been performed based on the gene expression of muscle mass during aging by microarray technology ([@ref-6]; [@ref-21]; [@ref-57]). Although these analyses of muscle biopsies have been used to detect new genes and pathways associated with muscle function, there are still some limitations relating to this approach. The different sample sources, array platforms, and analysis techniques may make it difficult to compare between different studies. Therefore, it seems essential to integrate different gene expression datasets derived from various microarray studies of the muscle aging process to overcome the limitations of individual datasets. This would resolve inconsistencies as well.

The current study aims to integrate gene expression profiles for identifying the differentially expressed genes (DEGs) of young and old skeletal muscle samples in both genders as well as to find hub genes. In addition, a proper understanding of the PPI interaction and hub proteins may provide some insights into further exploration of the pathogenic mechanism of sarcopenia.

Material and Methods
====================

Data attainment and preprocessing
---------------------------------

The gene expression data of sarcopenia has been obtained from the Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) ([@ref-3]). The following search terms were used: "sarcopenia," "muscle," and "age."

The studies included in this study compared gene expression profiles between the muscle mass of both old and young in both genders. Non-human studies and reviews were excluded. Applying the above-mentioned conditions, two types of gene expression data were selected---[GSE38718](GSE38718) ([@ref-34]) and [GSE25941](GSE25941) ([@ref-40])---which were performed based on the [GPL570](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL570) Affymetrix Human Genome U 133 plus 2.0 Array platform ([Table 1](#table-1){ref-type="table"}).
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###### Characteristics of the individual studies.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GEO ID                 Male/Female   Young/Old   Platform                                                              Sample source              Country   Year   Ref.
  ---------------------- ------------- ----------- --------------------------------------------------------------------- -------------------------- --------- ------ -----------
  [GSE38718](GSE38718)   21/21         22/20       [GPL570](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL570)\   Muscle (Biceps brachii)    USA       2013   [@ref-12]
                                                   Affymetrix Human Genome                                                                                           

  [GSE25941](GSE25941)   17/19         15/21       [GPL570](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL570)\   Muscle (Vastuslateralis)   USA       2012   [@ref-13]
                                                   Affymetrix Human Genome                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We used the MATLAB software (R2014a) to analyze the chip data. For the preprocessing step, we performed the log2 transformation and then applied the quantile normalization process to raw data to minimize the heterogeneity among microarray studies from different samples. In the next step, we chose a *p*-value less than 0.05 and log fold change (FC) \>2.0 as significant thresholds to obtain differentially expressed genes (DEGs) between old and young muscle mass groups for both men and women.

Detection of hub genes
----------------------

We used the Cytoscape software (version 3.2.1) for reconstructing the networks and structural analysis. We performed two different approaches for the structural analysis and function prediction: First, a Cytoscape plugin called GeneMANIA was used for building a gene--gene interaction network from a list of DEGs (<http://www.genemania.org/plugin/>) ([@ref-36]) as well as for analyzing the constructed network to provide gene function prediction. The hub genes of the network were detected using the cytoHubba plugin for Cytoscape and the node degree was chosen as a centrality index. ([@ref-13]). A node degree is explained with the number of neighbors connected directly to the node, while the nodes with higher degrees are considered as hubs.

Next, a protein--protein interaction (PPI) network analysis was performed as another structural approach to explore the functions of the DEGs. The BisoGenet plugin of Cytoscape (<https://omictools.com/bisogenet-tool>) was used to construct a PPI network based on the list of the DEGs ([@ref-35]). Next, a centrality analysis using the cytoHubba plugin was performed to explore hub proteins with high node degrees as a centrality index.

Pathway enrichment analysis of DEGs
-----------------------------------

We used two different online resources, ToppGene (<https://toppgene.cchmc.org/>) ([@ref-12]) and InnateDB (<http://www.innatedb.com/>) ([@ref-7]), to detect the biological functions and potential pathways of the DEGs. These websites perform function prediction based on gene ontology (GO) and KEGG enrichment analysis approaches. Enriched GO terms/KEGG pathways were selected based on a false discovery rate (FDR) \<0.01 as a threshold.

Results
=======

By the integrated analysis, we identified 41,715 DEGs, including 19 downregulated and 41,696 upregulated DEGs, in men. Among women, 3,015 DEGs were found with 2,874 upregulated and 141 downregulated genes. The full list of the DEGs has been provided in [Table S1](#supp-1){ref-type="supplementary-material"}. To identify potential hub genes, the node degree was considered as a centrality index in both upregulated and downregulated genes for both genders. The top hub genes for both genders have been demonstrated in [Table 2](#table-2){ref-type="table"} and [Table S2](#supp-2){ref-type="supplementary-material"} .
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###### Top hub nodes based on the GeneMANIA reconstructed network.
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  Men        Women                                                                                                                    
  ---------- ----------------------------------------------------- ----- ----------- ------------------------------------------------ ----
  RPL24      *Ribosomal Protein L24*                               117   PLIN1       *Perilipin 1*                                    39
  RPS3       *Ribosomal Protein S3*                                108   FABP4       *Fatty Acid Binding Protein 4*                   39
  RPL6       *Ribosomal Protein L6*                                107   TIMP4       *Tissue Inhibitor Of Metalloproteinase 4*        35
  RPS5       *Ribosomal Protein S5*                                106   ADH1B       *Alcohol Dehydrogenase 1B*                       34
  PSMA3      *Proteasome Subunit Alpha3*                           105   GPC3        *Glypican 3*                                     33
  RPL11      *Ribosomal Protein L11*                               103   PRL         *Prolactin*                                      32
  RPS16      *Ribosomal Protein S16*                               101   LPL         *Lipoprotein Lipase*                             31
  PSMA1      *Proteasome Subunit Alpha1*                           98    G0S2        *G0/G1 Switch 2*                                 30
  RPL12      *Ribosomal Protein L12*                               98    PCK1        *Phosphoenolpyruvate Carboxykinase 1*            30
  PSMB1      *Proteasome Subunit Beta1*                            96    GYG2        *Glycogenin 2*                                   29
  PSMA4      *Proteasome Subunit Alpha4*                           96    GPD1        *Glycerol-3-Phosphate Dehydrogenase 1*           29
  RPL27      *Ribosomal Protein L27*                               94    ADIPOQ      *Adiponectin*                                    29
  SERPINE2   *Serpin Family Member E2*                             12    MNDA        *Myeloid Cell Nuclear Differentiation Antigen*   32
  SERPINB2   *Serpin Family Member B2*                             12    S100A8      *S100 Calcium Binding Protein A8*                30
  SERPINE1   *Serpin Family Member E 1*                            11    ITGB6       *Integrin Subunit Beta 6*                        27
  ZMIZ1      *Zinc Finger MIZ-Type Containing 1*                   11    PROK2       *Prokineticin 2*                                 26
  SERPINB4   *Serpin Family Member B4*                             11    S100A9      *S100 Calcium Binding Protein A9*                25
  SERPINB3   *Serpin Family Member B3*                             10    ADCYAP1     *Adenylate Cyclase Activating Polypeptide 1*     23
  PIAS2      *Protein Inhibitor Of Activated STAT 2*               10    S100A12     *S100 Calcium Binding Protein A12*               23
  SERPINF1   *Serpin Family Member F1*                             9     RGS6        *Regulator Of G-Protein Signaling 6*             23
  SERPINA1   *Serpin Family Member A1*                             9     KPNA4       *Karyopherin Subunit Alpha 4*                    23
  HMSD       *Histocompatibility Minor Serpin Domain Containing*   9     ADCYAP1R1   *ADCYAP Receptor Type I*                         22
  SERPINE3   *Serpin Family Member E3*                             9     DUSP3       *Dual Specificity Phosphatase 3*                 22
  PIAS4      *Protein Inhibitor Of Activated STAT 4*               8     VEGFA       *Vascular Endothelial Growth Factor A*           22

GO analysis showed the enrichment of DEGs in biological processes, molecular functions, and cellular components. Among men, the enriched GO term for the biological process was the negative regulation of molecular function; the GO term for the cellular component was cytosolic ribosome; and serine-type endopeptidase inhibitor activity was significantly enriched for molecular functions.

We found that the enriched GO terms among women were chemokine production, lipid particle, and RAGE receptor binding for biological processes, molecular functions, and cellular components respectively. The full list of GO term categories enrichment analysis is shown in [Tables 3](#table-3){ref-type="table"} and [4](#table-4){ref-type="table"} in men and women respectively.

Furthermore, to explore the biological significance of the DEGs, the KEGG pathway enrichment analysis was also conducted. Among men, the most significantly enriched pathway was ribosome. Furthermore, the DEGs were significantly enriched in pathway in proteasome and amoebiasis. Among men, the most significantly enriched pathway was ribosome. Moreover, the DEGs were significantly enriched in the pathway in proteasome and amoebiasis. Among women, the peroxisome proliferator-activated receptor (PPAR) signaling pathway and the adipocytokine signaling pathway were highly enriched. Also, the Glycolysis / Gluconeogenesis was found to be significantly enriched ([Table 5](#table-5){ref-type="table"}).
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###### The enriched gene ontology (GO) categories of differentially expressed genes (DEGs) in men.
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  GO ID                                                            Terms                                                                 Count   *P*-value   FDR
  ---------------------------------------------------------------- --------------------------------------------------------------------- ------- ----------- ----------
  **Biological process**                                                                                                                                     
  [GO:0044092](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0044092)   negative regulation of molecular function                             16      1.86E−14    1.83E−11
  [GO:0030162](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0030162)   regulation of proteolysis                                             14      3.77E−14    1.85E−11
  [GO:0006614](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0006614)   SRP-dependent cotranslational protein targeting to membrane           8       2.00E−13    6.55E−11
  [GO:0006613](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0006613)   cotranslational protein targeting to membrane                         8       3.61E−13    8.13E−11
  [GO:0045047](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0045047)   protein targeting to ER                                               8       4.24E−13    8.13E−11
  [GO:0052548](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0052548)   regulation of endopeptidase activity                                  11      5.72E−13    8.13E−11
  [GO:0072599](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0072599)   establishment of protein localization to endoplasmic reticulum        8       5.79E−13    8.13E−11
  [GO:0052547](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0052547)   regulation of peptidase activity                                      11      1.06E−12    1.25E−10
  [GO:0016032](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0016032)   viral process                                                         13      1.14E−12    1.25E−10
  [GO:0044764](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0044764)   multi-organism cellular process                                       13      1.44E−12    1.41E−10
  [GO:0000184](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0000184)   nuclear-transcribed mRNA catabolic process, nonsense-mediated decay   8       1.58E−12    1.41E−10
  [GO:0070972](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0070972)   protein localization to endoplasmic reticulum                         8       2.20E−12    1.77E−10
  [GO:0044419](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0044419)   interspecies interaction between organisms                            13      2.53E−12    1.77E−10
  [GO:0044403](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0044403)   symbiosis, encompassing mutualism through parasitism                  13      2.53E−12    1.77E−10
  [GO:0032269](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0032269)   negative regulation of cellular protein metabolic process             14      7.06E−12    4.55E−10
  [GO:0043086](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0043086)   negative regulation of catalytic activity                             13      7.41E−12    4.55E−10
  **Cellular component**                                                                                                                                     
  [GO:0022626](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0022626)   cytosolic ribosome                                                    8       1.18E−12    1.14E−10
  [GO:0044391](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0044391)   ribosomal subunit                                                     8       2.67E−11    1.29E−09
  [GO:0005840](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005840)   ribosome                                                              8       2.81E−10    6.81E−09
  [GO:0044445](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0044445)   cytosolic part                                                        8       2.81E−10    6.81E−09
  [GO:0005839](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005839)   proteasome core complex                                               4       9.03E−09    1.32E−07
  [GO:0030529](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0030529)   intracellular ribonucleoprotein complex                               10      9.55E−09    1.32E−07
  [GO:1990904](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:1990904)   ribonucleoprotein complex                                             10      9.55E−09    1.32E−07
  [GO:0022625](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0022625)   cytosolic large ribosomal subunit                                     5       1.81E−08    2.19E−07
  [GO:0019773](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0019773)   proteasome core complex, alpha-subunit complex                        3       9.61E−08    1.04E−06
  [GO:0015934](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0015934)   large ribosomal subunit                                               5       1.75E−07    1.70E−06
  [GO:0000502](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0000502)   proteasome complex                                                    4       2.53E−06    2.23E−05
  [GO:0005925](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005925)   focal adhesion                                                        6       7.03E−06    5.62E−05
  [GO:0005924](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005924)   cell-substrate adherens junction                                      6       7.56E−06    5.62E−05
  [GO:0030055](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0030055)   cell-substrate junction                                               6       8.12E−06    5.62E−05
  **Molecular function**                                                                                                                                     
  [GO:0004867](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0004867)   serine-type endopeptidase inhibitor activity                          9       1.96E−15    2.05E−13
  [GO:0004866](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0004866)   endopeptidase inhibitor activity                                      9       3.97E−13    1.66E−11
  [GO:0061135](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0061135)   endopeptidase regulator activity                                      9       5.44E−13    1.66E−11
  [GO:0030414](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0030414)   peptidase inhibitor activity                                          9       6.33E−13    1.66E−11
  [GO:0061134](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0061134)   peptidase regulator activity                                          9       4.39E−12    9.22E−11
  [GO:0003735](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0003735)   structural constituent of ribosome                                    8       1.66E−10    2.91E−09
  [GO:0004857](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0004857)   enzyme inhibitor activity                                             9       6.83E−10    1.03E−08
  [GO:0004298](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0004298)   threonine-type endopeptidase activity                                 4       1.20E−08    1.40E−07
  [GO:0070003](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0070003)   threonine-type peptidase activity                                     4       1.20E−08    1.40E−07
  [GO:0019843](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0019843)   rRNA binding                                                          5       1.98E−08    2.08E−07
  [GO:0030234](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0030234)   enzyme regulator activity                                             9       2.55E−06    2.44E−05
  [GO:0005198](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005198)   structural molecule activity                                          8       2.88E−06    2.52E−05

10.7717/peerj.5239/table-4

###### The enriched gene ontology (GO) categories of differentially expressed genes (DEGs) in women.
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  GO ID                                                            Terms                                                  Count   *P*-value   FDR
  ---------------------------------------------------------------- ------------------------------------------------------ ------- ----------- ----------
  **Biological process**                                                                                                                      
  [GO:0032602](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0032602)   chemokine production                                   5       7.97E−08    1.01E−04
  [GO:0006954](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0006954)   inflammatory response                                  9       1.23E−07    1.01E−04
  [GO:0050727](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0050727)   regulation of inflammatory response                    7       1.75E−07    1.01E−04
  [GO:0048878](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0048878)   chemical homeostasis                                   10      5.74E−07    2.17E−04
  [GO:0050729](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0050729)   positive regulation of inflammatory response           5       6.29E−07    2.17E−04
  [GO:1903034](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:1903034)   regulation of response to wounding                     7       1.53E−06    4.40E−04
  [GO:0032103](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0032103)   positive regulation of response to external stimulus   6       2.84E−06    7.02E−04
  [GO:1903036](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:1903036)   positive regulation of response to wounding            5       3.56E−06    7.68E−04
  [GO:0070488](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0070488)   neutrophil aggregation                                 2       4.69E−06    9.00E−04
  [GO:0009967](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0009967)   positive regulation of signal transduction             10      6.59E−06    1.14E−03
  [GO:0016051](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0016051)   carbohydrate biosynthetic process                      5       7.46E−06    1.17E−03
  **Cellular component**                                                                                                                      
  [GO:0005811](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005811)   lipid particle                                         3       7.83E−05    6.97E−03
  [GO:0005615](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005615)   extracellular space                                    8       2.60E−04    1.16E−02
  **Molecular function**                                                                                                                      
  [GO:0050786](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0050786)   RAGE receptor binding                                  3       3.98E−07    6.25E−05
  [GO:0035662](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0035662)   Toll-like receptor 4 binding                           2       9.34E−06    4.04E−04
  [GO:0031406](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0031406)   carboxylic acid binding                                5       1.13E−05    4.04E−04
  [GO:0043177](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0043177)   organic acid binding                                   5       1.20E−05    4.04E−04
  [GO:0005102](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005102)   receptor binding                                       10      1.29E−05    4.04E−04
  [GO:0005504](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0005504)   fatty acid binding                                     3       2.85E−05    7.31E−04
  [GO:0050544](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0050544)   arachidonic acid binding                               2       3.26E−05    7.31E−04
  [GO:0050543](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0050543)   icosatetraenoic acid binding                           2       4.34E−05    7.97E−04
  [GO:0050542](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0050542)   icosanoid binding                                      2       5.58E−05    7.97E−04
  [GO:0035325](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0035325)   Toll-like receptor binding                             2       5.58E−05    7.97E−04
  [GO:1901567](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:1901567)   fatty acid derivative binding                          2       5.58E−05    7.97E−04
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###### The significantly enriched KEGG pathways of differentially expressed genes (DEGs) in both genders.
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  Pathway term                      Gene count   *P*-value     FDR
  --------------------------------- ------------ ------------- -------------
  **Men**                                                      
  Ribosome                          8            9.05E−11      7.40E−10
  Proteasome                        3            1.00E−04      5.79E−04
  Amoebiasis                        3            0.001197846   0.001632358
  **Women**                                                    
  PPAR signaling pathway            5            3.91E−07      2.15E−05
  Adipocytokine signaling pathway   2            0.010953677   0.035438366
  Glycolysis/Gluconeogenesis        2            0.010069903   0.036922978

![The constructed PPI network of the top up- and down-regulated DEGs in Men (A) and Women (B).\
Nodes denote proteins; edges denote interactions between two proteins. Red and blue nodes represent products of down- and up-regulated DEGs, respectively.](peerj-06-5239-g001){#fig-1}

The interaction network of top upregulated and downregulated DEGs were established by the Cytoscape software. In the PPI network of men, there were 1,189 nodes and 28,982 edges, while 454 nodes and 4,556 edges were in the network of women. Among men, three nodes with the highest degree were defined as hub proteins, including Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1, degree = 409), Cullin 3 (CUL3, degree = 336), and P53 (degree = 276). The significant hub proteins in women contained NTRK1 (degree = 168), CUL3 (degree = 133), and P53 (degree = 104) ([Fig. 1](#fig-1){ref-type="fig"}).

Discussion
==========

The molecular mechanisms of skeletal muscle maintenance/development involve an interplay between multiple signaling pathways. In normal conditions, a network of pathways, genes, and interconnected proteins serves to control hypertrophic and atrophic messages with the balance between muscle protein synthesis and proteolysis. The key signaling pathway for muscle protein synthesis is insulin-like growth factor-1- (IGF1), PtdIns-3-OH kinase-(PI3K)-AKt. IGF1- PI3K-AKt signaling promotes skeletal muscle hypertrophy by activating the mammalian target of rapamycin (mTOR). The activation of mTOR in response to growth factors, feeding, and increased mechanical loading is a key step in inducing muscle hypertrophy by increasing protein synthesis. Additionally, Akt inhibits protein degradation through Forkhead box O (FOXO)-mediated proteasome activity ([@ref-18]; [@ref-23]; [@ref-42]). Proteolytic systems, including calpain, the ubiquitin--proteasome pathway, and the autophagy--lysosomal pathway, are responsible for protein degradation in muscle cells ([@ref-39]). The ubiquitin--proteasome system is a key mechanism for the control of metabolic enzymes or dedicated regulatory proteins ([@ref-5]).

According to this content, the onset of age-related muscle loss (sarcopenia) is developed by an imbalance between muscle protein synthesis and proteolysis. Sarcopenia is an age-related disease that has rapidly increased around the world. The understanding of the molecular mechanisms for sarcopenia is an important factor to develop better detection, diagnosis, and novel therapeutic targets of this disease. Increased proteolysis and decreased protein synthesis in sarcopenia is attributed to the activity of the ubiquitin--proteasome system interconnected with autophagy.

Most studies on sarcopenia focused on individual genes and lacked global data. Given that the main pathways interact with other mechanisms, an integrated look could be considered as an essential aim to identify hub genes and proteins--it may improve the clinical management of disease. In this study, we focused on the DEGs between old and young muscle mass based on two microarray studies to identify the key genes, pathways, and hub proteins involved in the development of low muscle mass as the main parameter of sarcopenia.

In total, 41,715 genes were filtered as the DEGs with 41,696 upregulated and 19 downregulated genes in men. Among women, we identified 3,015 DEGs, which included 2,874 upregulated and 141 downregulated genes.

Some evidence indicated the importance of differences in gene expressions in explaining muscle development and muscle function between men and women ([@ref-17]; [@ref-43]; [@ref-47]).

However, the basis for these sex-related differences is not clear: estrogen and androgen elements might influence the sex-related differences in gene expressions ([@ref-44]). It seems that some effects of testosterone on gene expressions might be limited to the period of rapid muscle growth after puberty ([@ref-53]). The significant differences in body fat proportions between men and women are another possibility of causing these differences in gene expressions ([@ref-44]).

Some evidence was collected for muscle gene expression profiles in men and women ([@ref-44]; [@ref-51]; [@ref-52]). [@ref-53] reported that sex-related differences in muscle expressions, such as genes coding mitochondrial proteins and ribosomal biogenesis, could contribute to differences in the muscle size of men and women. Another study found that sex had the strongest influence on muscle gene expressions, with differential expressions (\>1.7-fold) being observed in this regard ([@ref-44]). In addition, many age-related changes in muscle mass, such as insulin resistance, pro-inflammatory state, elevation oxidative stress, and reduced neuronal stimulation, appear to be influenced by sex. Therefore, aging of muscle is regulated by different mechanisms in men and women ([@ref-27]; [@ref-38]).

In addition, many age-related changes in muscle mass, such as insulin resistance, pro-inflammatory state, elevation oxidative stress, and reduced neuronal stimulation, appear to be influenced by sex. Therefore, aging of muscle is regulated with different mechanisms in men and women.

We found that the genes involved in ribosome biogenesis, such as RPL24, RPS3, and other RPL families, were significantly upregulated with aging in old men.

Ribosome has an essential role in the regulation of cell proliferation and growth and homeostasis in organisms. Therefore, muscle hypertrophy requires an increase in ribosome biogenesis in smooth and skeletal muscle mass. On the other hand, mTOR is a master regulator of ribosome biogenesis by promoting the translation of the mRNAs and the transcription of rRNAs ([@ref-11]). Some studies have revealed that the ability of skeletal muscle to hypertrophy in response to anabolic stimulation of protein synthesis is blunted in older individuals ([@ref-26]; [@ref-30]). Recently, [@ref-30] found that despite the ribosome protein gene expression being higher in the aged mice group, ribosome biogenesis was significantly impaired at the level of ribosomal DNA (rDNA) transcription--it had been mediated by RNA polymerase I in aged skeletal muscle. They also revealed that the greatest aged-related differences in the gene expression were RPL24 and especially RPL11. These results are consistent with another study that found that increases in muscle mass were negatively correlated with the expression of ribosomal genes ([@ref-19]). Therefore, our results and these reports show that the blunted hypertrophic response in old muscle was primarily the attenuated translational capacity at the level of rDNA transcription more than changes in the gene expression.

In women, our findings have shown that the expression of genes involved in lipid storage, such as, PLIN1, FABP4, and LPL, were upregulated in older individuals.

Our results might suggest developing ectopic lipid infiltration in muscle, and therefore, it may be directly linked with insulin resistance in older people. A dramatic increase in PLIN1 was observed in older women when compared to young women. Age-related loss of muscle mass depends on the decrease in muscle quality and accumulation of inter-muscular adipose tissue (IMAT). Fat accumulation could occur as intra-muscular triglycerides (IMTG) deposition in lipid droplets, which are associated with the perilipin family ([@ref-4]). However, previous studies found that perilipin is a protein that coats lipid droplets in adipocytes and acts as a protective factor from lipolysis ([@ref-29]; [@ref-46]). [@ref-14] showed that an increased PLIN expression during aging is linked to fatty acid storage rather than utilization. It is known that fat accumulation is linked with a high flow of lipid intermediates---this causes the upregulation of peroxisome proliferator-activated receptors (PPARs) and an increased formation of oxidized lipid and Reactive Oxygen Species (ROS), thus triggering mitochondrial dysfunction and p53 activation that eventually lead to skeletal muscle atrophy in aging people ([@ref-49]).

Another most upregulated DEG was fatty acid-binding protein 4 (FABP4), which is expressed in adipose tissue, heart, and skeletal muscle. It plays an important role in the development of insulin resistance and metabolic disorders. FABP4 has been shown to be released from adipocytes in a non-classical pathway associated with lipolysis, possibly acting as an adipokine ([@ref-20]; [@ref-28]).

Consistent with the upregulation of lipid depositions genes in the muscle of older people, the genes involved in extracellular matrix (ECM) remodeling were also expressed at higher levels in older women than in young women ([@ref-9]; [@ref-31]). The ECM provides a framework for the transmission of force and maintains a suitable environment for cellular functions. Disruption of the balance between the production of active enzymes and their inhibition may result in diseases associated with uncontrolled ECM turnover, inflammation, cell growth, and migration, such as arthritis, cardiovascular disease, cancer, and neurological disorders. The tissue inhibitors of metallo-proteinases (TIMPs) such as TIMP4, are endogenous inhibitors of these metallo-proteinases and are consequently important regulators of ECM turnover, tissue remodeling, and cellular behavior ([@ref-8])*.* These genes might play a role in the decline of anabolic response and insulin activity in older skeletal muscle.

Studies showed that IMATs are not always related to obesity and that healthy non-obese women can store about 60% more lipids than men in the skeletal muscle mass. Different lines of evidence have indicated that lipid accumulation inside muscle cells leads to insulin resistance ([@ref-24]). Perhaps it is the reason that many diseases related to insulin resistance, such as Type 2 diabetes, metabolic syndrome, and obesity, are higher among women.

KEGG pathway enrichment analysis showed that ribosome biogenesis was the most significantly enriched pathway for the identified DEGs in men. As mentioned, ribosome biogenesis is a central mechanism to regulate protein synthesis and control skeletal muscle size in response to anabolic and catabolic stimulation.

The most well-known cellular proteolytic system is the ubiquitinproteasome pathway (UPP), which is responsible for proteolysis ([@ref-41]). This is a system where proteins meant for destruction are enzymatically tagged with the polypeptide ubiquitin via E3 ubiquitin ligases. Muscle wasting is characterized by increased protein degradation via the UPP, enlarged ubiquitin conjugation to muscle proteins, and upregulation of ubiquitinprotein ligases such as CUL3 ([@ref-32]).

The peroxisome proliferator-activated receptor (PPAR) pathway is also a highly enriched pathway in women. It is a ligand-activated transcription factor with critical roles in the regulation of lipid catabolism, glucose homeostasis, and inflammation. In addition, there is strong evidence that PPAR has a role in cycle control, differentiation, and apoptosis. Also, the PPAR regulatory pathway plays an essential role in the regulation of diverse biologic processes in metabolic disorders such as diabetes, hypertension, and cardiovascular diseases ([@ref-37]).

Moreover, the KEGG pathway analysis shows that the adipocytokine signaling pathway is another highly enriched pathway in women. This pathway defines the signaling cascades arising from the adipocytokines that have been associated with insulin resistance/sensitivity and inflammation.

In our results, the expression of adiponectin gene increases in older women. Although adiponectin increases insulin sensitivity in various tissues ([@ref-59]), lipid toxicity and oxidative stress in skeletal muscle could induce the overexpression of ADIPOQ, which might potentially work as a cellular protective mechanism ([@ref-16]). Therefore, the upregulation of ADIPOQ in our study may suggest a higher propensity to develop oxidative stress and lipid storage in the muscle of elderly people.

Although hub genes and pathways are different in men and women, NTRK1, CUL3, and P53 are three significant hub proteins in PPI networks in both genders.

The common ligands of TRK receptors, a family of tyrosine kinases that regulates synaptic strength and plasticity in the nervous system, are neurotrophins. Neurotrophins are a family of growth factors critical to the functioning of the nervous system. The activation of TRK receptors by neurotrophin binding may activate the signal cascades, thereby promoting survival and other functional regulation of cells. The neurotrophic factors expressed in skeletal muscle are essential for motoneuron survival and muscle fiber innervation during development ([@ref-45]).

The Kelch family is considered as regulators of the processes of proliferation and/or differentiation of skeletal muscle development and function. Essentially, many Kelch proteins act as substrate-specific adaptors for Cullin E3 ubiquitin ligase (Cul3), an important component of the ubiquitin--proteasome system that regulates proteolysis ([@ref-22]).

Another hub protein in the PPI network was P53. It is recognized as a central regulator of cell cycle and apoptosis. During aging, P53 has been proposed to regulate both homeostasis and atrophy of skeletal muscle (sarcopenia). However, the exact molecular function of P53 remains to be clearly defined. A number of stress signals, such as oxidative stress, activate P53 and bind to the peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) promoter for regulating an antioxidant response essential for skeletal muscle homeostasis ([@ref-1]). The nuclear S-nitrosylation of P53 significantly declines in skeletal muscle during aging, thus leading to an impairment of the homeostasis of skeletal muscle. Therefore, it could be a contributing factor of sarcopenia conditions and other skeletal muscle pathologies associated with oxidative stress ([@ref-2]).

The important point of our study is that the hub proteins derived from the PPI network and the hub genes are interconnected ([Fig. 2](#fig-2){ref-type="fig"}).

![Schematic representations of the identified hub genes and proteins of muscle development, according to our results.](peerj-06-5239-g002){#fig-2}

As mentioned, ribosome biogenesis genes were hub genes with the differential expression between old and young men. Recent studies found that RPs have additional extra-ribosomal functions, independent of protein biosynthesis, for the regulation of diverse cellular processes. Some triggers such as DNA damage, RP mutations, and nutrient deprivation would know as ribosomal stress to cause the release of RPs from the nucleus. Next, some RPs regulate apoptosis, cell cycle arrest, cell proliferation, neoplastic transformation, and cell migration and invasion through the activation of P53 ([@ref-56]; [@ref-58]). In our study, it seems that the upregulation of RPL24, RPLS3, and other RPs in the muscle of old men causes the activation of P53 and leads to cell cycle arrest and apoptosis.

In addition, the proteasome seems to play a crucial role in regulating the RP turnover through ubiquitination. It has been shown that members of the cullin family, such as NEDD8 (neural-precursor-cell-expressed developmentally downregulated 8) can have an opposite effect on cell proliferation and survival of ribosome ([@ref-10]; [@ref-55]). Also, another mechanism of ribosome degradation is a selective autophagy called ribiophagy. For doing ribiophagy, ribosomes need to be ubiquitinated to recognize authophagy membranes ([@ref-10]).

Therefore, these mechanisms could be involved in the regulation between proliferation and cell cycle arrest by balancing the ribosome biogenesis and activating P53 or the proteolytic factors.

Our results show that genes involved in lipid storage are hub genes. NTRK1, Cullin 3 (CUL3), and P53 have been identified as hub proteins in older women. Some studies found that the association between these genes and proteins could be involved to develop old muscle mass.

In our study, we found P53 in the PPI network and the genes involved in lipid storage were the important factors in older women ([Fig. 2](#fig-2){ref-type="fig"}). Another study showed that a strong correlation between the amount of P53 and the PLIN expression in aged muscle ([@ref-14]). P53 is known to play a role in regulating muscle atrophy. It seems that P53 activation through the PPAR pathway, possibly triggered by the accumulation of PLINs and excessive fatty acids as toxic lipid intermediates, decrease the muscle mass in older people ([@ref-50]). In additional, insulin is an anti-proteolytic factor, but proteolysis increases t in insulin resistance states such as accumulation of PLINs and excessive fatty acids in muscle ([@ref-14]; [@ref-54]).

The present results should be interpreted within the context of strengths and potential limitations. To the best of our knowledge, this is the first report using an integrated approach to identify DEGs in muscle mass between old and young individuals in both genders. We also tried to choose the most commonly used software and algorithms for structural analysis. The DEGs in the current study have been predicted without experimental evidence. Therefore, future research would be needed to prove the results of this study.

Conclusion
==========

By integrating the analysis of multiple gene expression profiles, we have proposed that the ribosome biogenesis genes and those involved in lipid storage would be promising markers for sarcopenia in men and women, respectively. According to PPI network analysis, neurotrophic factors expressed in skeletal muscle are essential for motoneuron survival and muscle fiber innervation during development. Cullin E3 ubiquitin ligase (Cul3) is an important component of the ubiquitin--proteasome system which regulates the proteolysis. P53 is also recognized as a central regulator of the cell cycle and apoptosis. These hub proteins might be involved in aging muscle and sarcopenia. The important point of our study is that hub proteins and hub genes are interconnected. These results could be considered meaningful for future diagnosis and therapy of sarcopenia.
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